AN2 Therapeutics Receives FDA Clearance for Epetraborole Trial in Mycobacterium abscessus Lung Disease
核心洞察
AN2 Therapeutics received FDA clearance to proceed with a 90-patient investigator-initiated trial evaluating epetraborole in patients with Mycobacterium abscessus lung disease (搜索).
The multicenter, randomized, double-blind, placebo-controlled study will focus on early-stage, treatment-naïve patients and aims to address the significant unmet need for oral therapies.
Currently, no FDA-approved therapeutics exist for this difficult-to-treat chronic lung infection, with patients relying on complex, off-label intravenous drug regimens.
AN2 Therapeutics has received FDA clearance to proceed with an investigator-initiated trial (IIT) evaluating epetraborole in patients with Mycobacterium abscessus lung disease (搜索), marking a significant milestone in addressing a critical unmet medical need. The U.S. Food and Drug Administration cleared Oregon Health & Science University's (OHSU) Investigational New Drug (IND) application, enabling the company to advance its oral treatment option for patients currently dependent on complex, off-label intravenous therapies.
Study Design and Leadership
The multicenter, randomized, double-blind, placebo-controlled, prospective clinical study will be led by Dr. Kevin Winthrop, Professor of Public Health and Infectious Diseases at OHSU, in collaboration with investigators across an estimated 10-15 sites in the United States. The trial will enroll approximately 90 patients and is expected to initiate patient enrollment in the first quarter of 2026.
"Current treatment for M. abscessus relies on off-label, complex intravenous drug regimens that are difficult to tolerate, provide modest efficacy and are burdensome to patients," said Dr. Winthrop. "Patients need oral therapies that are efficacious and well tolerated, and epetraborole has the potential to address this unmet need in M. abscessus patients."
Addressing Critical Treatment Gaps
Mycobacterium abscessus lung disease (搜索) represents a severe, rapidly progressive nontuberculous mycobacterial (NTM) infection that is notoriously difficult to treat. Currently, no FDA-approved therapeutics exist for this challenging chronic lung infection, and the pathogen demonstrates resistance to most oral antibiotics. Patients often require prolonged, multi-drug intravenous regimens that are poorly tolerated and frequently ineffective.
The study design represents a strategic shift from AN2's previous research approach. While the company's epetraborole trial in mycobacterium avium complex (搜索) (MAC) focused on patients with advanced disease, this M. abscessus trial will enroll a population with treatment-naïve disease. This approach should allow researchers to evaluate the potential impact of the novel candidate in a related patient population with similarly urgent therapeutic needs.
Market Opportunity and Clinical Significance
According to AN2 Therapeutics, an estimated 120,000-150,000 people in the United States live with NTM lung disease, with 10-15% of cases caused by M. abscessus. This represents both a significant unmet medical need and a meaningful market opportunity for the biopharmaceutical company.
"The IND clearance is a significant milestone as we evaluate epetraborole as potentially the first FDA-approved therapy for patients with M. abscessus," said Eric Easom, Co-Founder, Chairman, President and CEO of AN2 Therapeutics. "Positive data from this study could establish human proof of concept and inform the design of a subsequent pivotal trial."
Therapeutic Mechanism and Platform
Epetraborole is an investigational, once-daily oral therapy designed to inhibit leucyl-tRNA synthetase (搜索), a mechanism that has demonstrated activity across multiple NTM species. The compound represents part of AN2's broader boron-based therapeutic platform, which the company is advancing across infectious diseases and other therapeutic areas.
The investigator-initiated, proof-of-concept study aims to assess the efficacy, safety, and pharmacokinetics of epetraborole in patients with M. abscessus. Results from this trial are expected to provide crucial data to support further development of epetraborole for patients with this challenging infection and potentially establish a foundation for future pivotal trials.